Menu

Recent Interviews

Gary Cope, President and CEO, Barsele Minerals

Gary Cope
President and CEO | Barsele Minerals
Suite 1130 - 1055 W. Hastings Street, V6E 2E9 Vancouver (CN)

info@barseleminerals.com

+1(604) 687-8566

Interview Barsele Minerals: 'I have never seen a project with such good general conditions'.


Sébastien Plouffe, CEO and Director, Defence Therapeutics

Sébastien Plouffe
CEO and Director | Defence Therapeutics
1680 – 200 Burrard Street, V6C 3L6 Vancouver (CN)

info@defencetherapeutics.com

+1 (514) 947 2272

Interview Defence Therapeutics: Platform strategy the key to success


Humphrey Hale, CEO, Managing Geologist, Carnavale Resources Ltd.

Humphrey Hale
CEO, Managing Geologist | Carnavale Resources Ltd.
Level 2, Suite 9 389 Oxford Street, WA 6016 Mount Hawthorn (AUS)

info@carnavaleresources.com

Interview Carnavale Resources: Good cards for long-term success


12. April 2021 | 08:30 CET

BioNTech, Formycon, Psybio Therapeutics: A chance for normality?

  • Biotechnology
Photo credits: pixabay.com

It is a matter of course: The desire for normality! Things have not been normal over the last 12 months, which everyone is now feeling. Our society has had a lot to shoulder since the turn of the millennium. The extreme increase in radicalism, the emergence of dangerous dictators and incompetent politicians, the polarization of beliefs, the explosive development of wealth in shares and real estate owners with simultaneous global impoverishment, the excessive indebtedness of the states, and now, a worldwide pandemic of unimagined proportions. It takes a good deal of imagination to believe in a "normalization" and then a more philosophical question quickly arises: What does an economic reality with and after the pandemic look like?

time to read: 3 minutes by André Will-Laudien
ISIN: US09075V1026 , DE000A1EWVY8 , CA6936971044


 

Author

André Will-Laudien

Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

About the author


BioNTech - Vaccine also for adolescents

BioNTech SE from Mainz was in the right place at the right time. The German biotechnology company has been listed on the stock exchange since the end of 2019. It has focused on developing and producing active immunotherapies for the treatment of cancer and other serious diseases. BioNTech's main focus today is research into mRNA-based drugs. These are considered for use as individualized cancer immunotherapies, vaccines against infectious diseases and protein replacement therapies for rare diseases.

The Company caused a sensation when the Federal Republic of Germany became involved in researching a Covid vaccine very quickly. Then came the cooperation with the pharmaceutical giant Pfizer from the USA, known to everyone through the sexual enhancer Viagra. At the beginning of 2021, a Covid-19 vaccine was finally ready to be used worldwide with an efficacy of over 90%. A tremendous German success story, even if in the USA, people often only talk about Pfizer.

Now comes more good news from the USA. The manufacturers Pfizer and BioNTech want to use their Corona vaccine in the USA in adolescents aged 12 and older. An application to expand the existing emergency approval for the vaccine has already been submitted to the Food and Drug Administration (FDA). The use of the vaccine in the US has only been approved for ages 16 and older. If the approval of the authority comes, this would once again boost the all-important vaccination rate worldwide. With the news, the BioNTech share easily surpasses EUR 100 again and is heading for its old high of EUR 109.5. As a result, a new upward cycle could be initiated.

Formycon - No longer far away

There have been several announcements at Formycon in recent weeks. From a pandemic control perspective, the most important of these is that FYB207, the compound under development, is even more effective against newer, more infectious mutations of SARS-CoV-2, such as the UK variant B.1.1.7, than against earlier less infectious variants. A study published in December 2020 already showed that the efficacy of FYB207 is not affected by so-called spike protein mutations. Spike protein mutations threaten the effectiveness of both vaccines and the majority of antibodies against SARS-CoV-2.

Since we can continue to assume that governments worldwide will not implement mandatory vaccination, the combination of the lack of compulsory vaccination and the non-rare immunodeficiencies can conclude that new SARS-CoV-2 infections will persist indefinitely. Looking only at the Western Hemisphere, Europe and North America, we can continue to expect about 300,000 SARS-CoV-2-related hospitalizations per year. So there is an urgent need for drugs that both mitigate the course and reduce the rate of new infections. Formycon will make a significant contribution here.

We expect Formycon to initiate a Phase I/II study with FYB207 as early as the end of 2021. Assuming that this study's result is positive, we will very quickly apply for emergency approval for FYB207. As a result, the drug could be on the market as early as 2022. The share is currently consolidating in the EUR 58 to EUR 66 band. More news is likely to be needed for the next share price surge.

PsyBio Therapeutics Corp. - Moving forward with innovations

Florida-based PsyBio Therapeutics Corp. is moving forward. PsyBio is a biotechnology company developing novel formulations of psychoactive drugs produced by genetically engineered bacteria to treat mental and other disorders. The research team has several years of drug development experience based on synthetic biology and its clinical applications.

They have just begun collaboration with the Advanced Biofuels and Bioproducts Process Development Unit, a national laboratory of the US Department of Energy, for the process development of a proprietary biosynthetic formulation of norbaeocystin. Norbaeocystin is an analog of psilocybin and is not a controlled substance. The Company has begun Phase 1 of this process, including technical transfer of analytical chemistry. The goal here is to identify capture methods for fermentation products as well as key raw materials. Work on this is fully underway.

By continuing its efforts in this research field, PsyBio expects to begin scaling up the production of its own biosynthetic norbaeocystin in preparation for use in clinical trials in the near future. An important point here is to develop more nature-inspired psychedelic therapeutics with improved properties over psilocybin monotherapy. Potential efficacy against depression, anxiety, PTSD, and substance abuse is hypothesized and will be clinically demonstrated through the trials. For PsyBio, this would clear the way for exponential growth.

PsyBio's stock is currently trading between CAD 0.37 and CAD 0.45 in Canada. The corresponding market capitalization is about CAD 22 million. This is undoubtedly only the beginning of a longer story.


Author

André Will-Laudien

Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

23. July 2021 | 11:37 CET | by André Will-Laudien

CureVac, XPhyto Therapeutics, BioNTech, NanoRepro - Continuous testing or vaccination or both?

  • Biotechnology

Public confusion reigns. The pandemic seems to be locked in chains over the summer, and the population is happy about initial relief with incidences below 10. But now, the first vacationers are already coming back, partly from risk or mutation areas and have to go for testing again as vaccinated persons. It is often forgotten that even those who have been fully vaccinated can be carriers of the virus and can also fall ill, so it should be clear to everyone that personal protective measures must continue to be kept high. Our life with the COVID virus will last much longer than many want to believe...

Read

20. July 2021 | 13:42 CET | by Nico Popp

Siemens Healthineers, Cardiol Therapeutics, CureVac: Where there is music to be heard by the end of the year

  • Biotechnology

Health is the highest good. Anyone who has ever experienced people having the "plug pulled" on them overnight can undoubtedly relate to this truism. Fortunately, medicine in this country is able to provide a quick remedy. A wide range of options are available for both diagnosis and therapy. In addition to laboratory analyses, imaging procedures also ensure that disease patterns can be narrowed down and, thus, treatments can be carried out in a targeted manner. Although our drugs are already powerful, new, more innovative approaches are emerging all the time. This development is also benefiting investors.

Read

19. July 2021 | 11:11 CET | by Armin Schulz

BioNTech, Defence Therapeutics, Siemens Healthineers - Winning the fight against cancer

  • Biotechnology

There are over 200 different types of cancer where degenerate cells begin to form tumors. The cost of the disease is estimated at USD 1,160,000,000,000 worldwide. It is no wonder that a lot of money goes into researching cancer drugs. Whoever makes the breakthrough here can make a lot of money. It would be desirable that one of the three companies presented today could find a solution, as that could save 9.6 million people a year. But it is not only drugs that promise profits but also prevention and diagnostics. Today we highlight three companies that have joined the fight against cancer.

Read